Get started

Stockpicks

ACADIA Pharmaceuticals Inc 🧙Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ACADLong
by yura_trades
2
NNOX, Ready for Round #4?I think Nanox has been heavily shortened on FDA news, which isn't surprising knowing the market's tricks. That said, it is accumulating and has been around the $33 price point for the past few days. I think now is the time where for the next few weeks, support levels can start picking up. It does have potential for a next wave bull run at these levels, and a real short squeeze is yet to happen in my opinion. That said, everything I say is on an opinion based basis. Invest at your own risk and do your own due diligence.
NASDAQ:NNOXLong
by gamer456148
2
Playboy PLBY is a Multi-BaggerThis is not my idea or research. This is an idea from one of my favorite analysts, Brian McGough, who is a retail director at Hedgeye Risk Management. He said GME GameStop was a potential 10-bagger when it was at $20 late last year, and he's recently said he thinks PlayBoy is a 10-bagger (from ~$20). The general thesis is that the old management is gone and new management will have an opportunity to pivot the company towards a global sex, health, and media market that has a size of something like 300 billion. Still great upside from here, I am long the stock from $40 and am buying every dip.
NASDAQ:PLBYLong
by Ludwig_Von_Mises
$ENTX PT 6-10 and higherEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase 2 clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase 2 clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
NASDAQ:ENTXLong
by UnknownUnicorn19246015
1
Annexon Inc long scenario 🧙Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ANNXLong
by yura_trades
ABT - STOCKS - 05. APR. 2021Welcome to our weekly trade setup ( ABT )! - 4 HOUR Bullish price turnover.. DAILY Multiple trend-change confirmations. WEEKLY Oversold market structure..expecting another push to the upside. - STOCKS SETUP BUY ABT ENTRY LEVEL @ 119.53 SL @ 117.13 TP @ Open Max Risk: 0.5% - 1%! (Remember to add a few pips to all levels - different Brokers!) Leave us a comment or like to keep our content for free and alive. Have a great week everyone! ALAN
NYSE:ABTLong
by DACapitalTrading
10
DHR - STOCKS - 07. APR. 2021Welcome to our weekly trade setup ( DHR )! - 4 HOUR Bullish waving market structure.. DAILY Bearish market turning bullish now! WEEKLY Expecting more upside towards towards previous highs and beyond. - STOCKS SETUP BUY DHR ENTRY LEVEL @ 224.85 SL @ 215.15 TP @ Open Max Risk: 0.5% - 1%! (Remember to add a few pips to all levels - different Brokers!) Leave us a comment or like to keep our content for free and alive. Have a great week everyone! ALAN
NYSE:DHRLong
by DACapitalTrading
43
Jumia $JMIA - investment idea 💡This stock been trading for a while in the demand zone, giving great opportunity to buy the dip for it's low risk and great target potential. I expect it to up if not today it will be in a few days. ❌ - Volume looks good bust still under the average ✅ - Double bottom ✅ - Bullish price action on the daily (Bullish Doji) ✅ - MACD ✅ - STOCH ✅ - Momentum ✅ - DeMarker ❌ - MA50 (-23.9%) ✅ - MA200 (+31.35%) ❌ - Pivots: (-10.46%) ⏰ - Breakout 1: $40.37 🚀 - Potential targets (🚀247% by 20/07/2021) 🪂 - If things goes wrong better to exit if $32.60 didn't hold 🚦 - Next entries in case if dropped: $26.82 ⚠️ - This idea is based on my technical analysis only. Do your research and trade on your own risk!
NYSE:JMIALong
by Bullwards
2
WSM Stock 10/04/21 Analysis 4H ChartNYSE:WSM - Trend Analysis - 📑Value: 10/20 📈Growth: 18/20 💰Profitability 16/20 🚀Momentum: 20/20 💸Earnings: 18/20 🖇️Total Score: 82/100 Data: Volume 857M Average Volume (3 months) 1.55M Previous Close $185.31 Open $183.97 Shares Outstanding 76.19M Technicals: ( Simple Moving Average ) 10D SMA $180.95 (+1.25%) 50D SMA $144.80 (+26.53%) 200D SMA $109.46 (+67.38%) Market Cap $14.12B Total Debt $1.53B Cash $1.20B Enterprise Value $14.5B Revenue $6.78B Gross Profit $2.65B Net Income $680.71M EPS Diluted $8.61 Free Cash Flow / Share $14.31
NYSE:WSMLong
by investor_kings
DBX Stock 10/04/21 Analysis 4H Chart- Trend Analysis - 📑Value: 10/20 📈Growth: 18/20 💰Profitability 16/20 🚀Momentum: 8/20 💸Earnings: 16/20 🖇️Total Score: 68/100 Data: Volume 4.10M Average Volume (3 months) 8.32M Previous Close $27.69 Open $27.46 Shares Outstanding 319.67M Technicals: ( Simple Moving Average ) 10D SMA $27.04 (-0.18%) 50D SMA $24.98 (+8.06%) 200D SMA $21.88 (+23.38%) Market Cap $11.16B Total Debt $1.12B Cash $1.12B Enterprise Value $11.15B Revenue $1.01B Gross Profit $1.50B Net Income -$256.30M EPS Diluted -$0.62 Free Cash Flow / Share $1.18
NASDAQ:DBXLong
by investor_kings
MSFT Stock 10/04/21 Analysis 4H ChartNASDAQ:MSFT - Trend Analysis - 📑Value: 10/20 📈Growth: 16/20 💰Profitability: 18/20 🚀Momentum: 18/20 💸Earnings: 18/20 🖇️Total Score: 80/100 Data: Volume 24.32M Average Volume (3 months) 30.38M Previous Close $253.25 Open $253 Shares Outstanding 7.54B Technicals: ( Simple Moving Average ) 10D SMA $241.41 (+5.98%) 50D SMA $237.64 (+7.66%) 200D SMA $218.99 (+16.83%) Market Cap $1.91T Total Debt $82.78B Cash $131.99B Enterprise Value $1.86T Revenue $153.28B Gross Profit $104.77B Net Income $51.31B EPS Diluted $6.71 Free Cash Flow / Share $6.66
NASDAQ:MSFTLong
by investor_kings
FB Stock 10/04/21 Analysis 4H Chart- Trend Analysis - 📑Value: 6/20 📈Growth: 16/20 💰Profitability 20/20 🚀Momentum: 18/20 💸Earnings: 16/20 🖇️Total Score: 76/100 Data: Volume 15.98M Average Volume (3 months) 21.17M Previous Close $313.02 Open $311.52 Shares Outstanding 2.41B Technicals: ( Simple Moving Average ) 10D SMA $297.51 (+5.03%) 50D SMA $274.65 (+13.77%) 200D SMA $266.95 (+17.05%) Market Cap $891.38B Total Debt $11.18B Cash $61.95B Enterprise Value $840.60B Revenue $85.97B Gross Profit $69.28B Net Income $29.15B EPS Diluted $10.09 Free Cash Flow / Share $8.29
NASDAQ:METALong
by investor_kings
CFRX a great risks/reward ratio! 🧙ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
CLong
by yura_trades
1